Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in Pharmacogenomics Reporter on July 31, 2011 titled “Appeals Court Decides Isolated DNA Patentable, Myriad’s Analytical Method Claims Not.” Brinckerhoff discusses the Court of Appeals for the Federal Circuit’s ruling that isolated gene sequences are patentable, stating that the decision could have a far-reaching impact on other patents and personalized medicine type claims. She adds that practitioners and patent holders may want to review pending and granted claims to determine if they are affected by recent decisions regarding gene patent eligibility.
People
Related News
06 February 2025
In the News
Vanessa Miller Assesses Panama Canal Discourse
Foley & Lardner LLP partner Vanessa Miller commented in SupplyChainBrain article, "The Fight for Control of the Panama Canal," lending important context to the recent headlines over the important waterway.
06 February 2025
In the News
Gregory Husisian Weighs in on Suspension of De Minimis Trade Exemption
Foley & Lardner LLP partner Gregory Husisian offered context on President Trump's recent trade actions on China in The Wall Street Journal article, "Why Trump Is Closing a Trade Exemption for China."
04 February 2025
In the News
Andrew Wronski on Tariff Fluidity – 'Keep on top of the issues'
Foley & Lardner LLP partner Andrew Wronski assessed the evolving shift in U.S. trade policy in the Milwaukee Business Journal article, "Trump tariffs won't disappear — so how should Wisconsin businesses prepare?"